FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890167655> ?p ?o ?g. }

• W2890167655 endingPage "97" @default.
• W2890167655 startingPage "88" @default.
• W2890167655 abstract "Background LY3039478 is an orally bioavailable selective Notch inhibitor. This phase 1a/b trial evaluated the safety, pharmacokinetics and antitumour activity of LY3039478 in patients with soft tissue sarcoma (STS) and gastrointestinal stromal tumour (GIST). Methods This multipart, phase 1 trial enrolled patients with refractory advanced/metastatic STS and GIST, measurable disease, Eastern Cooperative Oncology Group ≤1 and baseline tumour tissue. Eligible patients received LY3039478 50mg/75 mg three times per week, for 28-day cycle until disease progression. Safety assessments were based on Common Terminology Criteria for Adverse Events, V4.0. Tumour responses were assessed using Response Evaluation Criteria in Solid Tumours (RECIST 1.1) and Choi criteria. Primary objectives were to confirm the recommended phase 2 dose of LY3039478 and document the antitumour activity. Secondary objectives were safety and toxicity, pharmacokinetics (PK), progression-free survival (PFS) and overall survival (OS). Results Sixty-nine patients were enrolled and received LY3039478 (27 males, 42 females; median age 58, range 31–78). 16/37 (43%) patients with evaluable samples were positive for Notch 1 immunohistochemistry. Per RECIST 1.1, in leiomyosarcoma (LMS) group (n = 29), ten (36%) had stable disease (SD) and one (4%) had unconfirmed partial response (PR). In GIST group (n = 13), four (31%) had SD. Among other STS subtypes (n = 27), one patient with angiosarcoma had unconfirmed PR, six (21%) had SD. Median PFS was 1.9 months (95% confidence interval:1.6–3.3) for LMS, 1.9 months (0.3–6.1) for GIST and 1.7 months (1.4–2.2) for other STS groups. Median OS was 7.4 months (4.3–non-evaluable [NE]) for LMS, 16.5 months (3.9–16.5) for GIST and 5.6 months (3.4-NE) for other STS groups. Most common adverse events were diarrhoea, nausea, vomiting and decreased appetite. Conclusion LY3039478 suggested a modest clinical activity in patients with STS and GIST and had a manageable safety profile." @default.
• W2890167655 created "2018-09-27" @default.
• W2890167655 creator A5001102421 @default.
• W2890167655 creator A5004418792 @default.
• W2890167655 creator A5006585898 @default.
• W2890167655 creator A5013591523 @default.
• W2890167655 creator A5016367638 @default.
• W2890167655 creator A5019508283 @default.
• W2890167655 creator A5022978138 @default.
• W2890167655 creator A5023660150 @default.
• W2890167655 creator A5030914311 @default.
• W2890167655 creator A5035341984 @default.
• W2890167655 creator A5045084904 @default.
• W2890167655 creator A5046981381 @default.
• W2890167655 creator A5053506951 @default.
• W2890167655 creator A5069003135 @default.
• W2890167655 creator A5090082356 @default.
• W2890167655 date "2018-11-01" @default.
• W2890167655 modified "2023-09-22" @default.
• W2890167655 title "Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours" @default.
• W2890167655 cites W1574545886 @default.
• W2890167655 cites W1976128449 @default.
• W2890167655 cites W1987085807 @default.
• W2890167655 cites W1993355130 @default.
• W2890167655 cites W1999672487 @default.
• W2890167655 cites W2004916479 @default.
• W2890167655 cites W2019607817 @default.
• W2890167655 cites W2042082068 @default.
• W2890167655 cites W2055051701 @default.
• W2890167655 cites W2085682228 @default.
• W2890167655 cites W2107464631 @default.
• W2890167655 cites W2108549165 @default.
• W2890167655 cites W2109541355 @default.
• W2890167655 cites W2123534406 @default.
• W2890167655 cites W2123696077 @default.
• W2890167655 cites W2126959323 @default.
• W2890167655 cites W2139881001 @default.
• W2890167655 cites W2153293603 @default.
• W2890167655 cites W2154861644 @default.
• W2890167655 cites W2187201134 @default.
• W2890167655 cites W2284711770 @default.
• W2890167655 cites W2515846219 @default.
• W2890167655 cites W2559471841 @default.
• W2890167655 cites W2883812201 @default.
• W2890167655 doi "https://doi.org/10.1016/j.ejca.2018.08.012" @default.
• W2890167655 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30218977" @default.
• W2890167655 hasPublicationYear "2018" @default.
• W2890167655 type Work @default.
• W2890167655 sameAs 2890167655 @default.
• W2890167655 citedByCount "21" @default.
• W2890167655 countsByYear W28901676552019 @default.
• W2890167655 countsByYear W28901676552020 @default.
• W2890167655 countsByYear W28901676552021 @default.
• W2890167655 countsByYear W28901676552022 @default.
• W2890167655 countsByYear W28901676552023 @default.
• W2890167655 crossrefType "journal-article" @default.
• W2890167655 hasAuthorship W2890167655A5001102421 @default.
• W2890167655 hasAuthorship W2890167655A5004418792 @default.
• W2890167655 hasAuthorship W2890167655A5006585898 @default.
• W2890167655 hasAuthorship W2890167655A5013591523 @default.
• W2890167655 hasAuthorship W2890167655A5016367638 @default.
• W2890167655 hasAuthorship W2890167655A5019508283 @default.
• W2890167655 hasAuthorship W2890167655A5022978138 @default.
• W2890167655 hasAuthorship W2890167655A5023660150 @default.
• W2890167655 hasAuthorship W2890167655A5030914311 @default.
• W2890167655 hasAuthorship W2890167655A5035341984 @default.
• W2890167655 hasAuthorship W2890167655A5045084904 @default.
• W2890167655 hasAuthorship W2890167655A5046981381 @default.
• W2890167655 hasAuthorship W2890167655A5053506951 @default.
• W2890167655 hasAuthorship W2890167655A5069003135 @default.
• W2890167655 hasAuthorship W2890167655A5090082356 @default.
• W2890167655 hasConcept C112705442 @default.
• W2890167655 hasConcept C121608353 @default.
• W2890167655 hasConcept C126322002 @default.
• W2890167655 hasConcept C141071460 @default.
• W2890167655 hasConcept C142724271 @default.
• W2890167655 hasConcept C143998085 @default.
• W2890167655 hasConcept C16930146 @default.
• W2890167655 hasConcept C197934379 @default.
• W2890167655 hasConcept C207103383 @default.
• W2890167655 hasConcept C2775922572 @default.
• W2890167655 hasConcept C2776694085 @default.
• W2890167655 hasConcept C2777532014 @default.
• W2890167655 hasConcept C2777793932 @default.
• W2890167655 hasConcept C2778256501 @default.
• W2890167655 hasConcept C2778629024 @default.
• W2890167655 hasConcept C2778822529 @default.
• W2890167655 hasConcept C2779490328 @default.
• W2890167655 hasConcept C2779984678 @default.
• W2890167655 hasConcept C44249647 @default.
• W2890167655 hasConcept C71924100 @default.
• W2890167655 hasConcept C90924648 @default.
• W2890167655 hasConceptScore W2890167655C112705442 @default.
• W2890167655 hasConceptScore W2890167655C121608353 @default.
• W2890167655 hasConceptScore W2890167655C126322002 @default.
• W2890167655 hasConceptScore W2890167655C141071460 @default.
• W2890167655 hasConceptScore W2890167655C142724271 @default.
• W2890167655 hasConceptScore W2890167655C143998085 @default.

• next